The direct to patient sales option is a bid to lower prices in the US.
Copyright 2025 The Associated Press. All Rights Reserved
Novartis is starting a new chapter in US sales: On Monday, the pharmaceutical company announced that it will sell its psoriasis drug Cosentyx (secukinumab) directly to cash-paying patients in the US via a direct-to-patient (DTP) platform.
+Get the most important news from Switzerland in your inbox
This platform is set to launch on November 1, 2025. It will offer patients who have been prescribed the drug the opportunity to purchase it at a 55% discount on the list price.
According to the press release, Cosentyx is Novartis’ best-selling product in the US. It is a biologic approved for the treatment of various immune-mediated inflammatory diseases.
More
More
The high stakes fight over drug prices
“In the US, we have long recognised that we need new ways to reach patients more directly by removing barriers in the system,” Victor Bultó, President of Novartis in the US, is quoted as saying in the announcement. The launch of this new platform is a first step, and Novartis is looking to apply this offering to other drugs as well.
Through the DTP platform, Novartis will “offer Cosentyx to US patients at a price that reflects the average savings achieved by insurers and pharmacy benefit managers,” the press release continues.
Adapted from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
